Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ibrance
Ibrance
Pfizer, awaiting a final NICE verdict, doles out free Ibrance in the U.K.
Fierce Pharma
Sun, 05/7/17 - 10:23 am
Pfizer
Ibrance
NICE
UK
breast cancer
Rivals multiplying, Pfizer appeals to doctor preferences with Ibrance's latest label win
Fierce Pharma
Tue, 04/4/17 - 10:58 pm
Pfizer
Ibrance
Novartis
Kisqali
Eli Lilly
abemaciclib
HER-2 negative breast cancer
breast cancer
Pfizer's Ibrance Gets FDA Approval for Breast Cancer
Investopedia
Mon, 04/3/17 - 11:54 am
Pfizer
Ibrance
breast cancer
FDA
Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug?
Motley Fool
Wed, 03/15/17 - 09:52 pm
Novartis
Pfizer
breast cancer
Ibrance
Kisqali
Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer
Endpoints
Tue, 03/14/17 - 09:38 am
Pfizer
Novartis
LEE011
Ibrance
ribociclib
Kisqali
breast cancer
UK cost watchdog says Pfizer's Ibrance too pricey
BioPharma Dive
Tue, 02/7/17 - 10:21 am
UK
Pfizer
Ibrance
drug pricing
breast cancer
Pfizer's 3 Fastest-Growing Drugs
Motley Fool
Wed, 02/1/17 - 09:58 am
Pfizer
Ibrance
Eliquis
Xeljanz
3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference
Motley Fool
Thu, 01/12/17 - 09:19 am
Pfizer
JPMHC 2017
M&A
competition
taxes
Ibrance
Pfizer Has Strong Track Record since 2010
Market Realist
Fri, 12/16/16 - 11:29 am
Pfizer
drug approvals
Ibrance
Prevnar 13
Inlyta
Xalkori
Xeljanz
How Could Pfizer Drive Growth for Ibrance?
Market Realist
Mon, 12/12/16 - 02:49 pm
Pfizer
Ibrance
breast cancer
Ibrance May Continue to Dominate Breast Cancer Space in 2016
Market Realist
Tue, 11/15/16 - 09:38 am
Ibrance
Pfizer
breast cancer
Pfizer wins EU's approval for Ibrance as Novartis readies rival drug
Yahoo/Reuters
Thu, 11/10/16 - 11:21 am
Pfizer
Europe
Ibrance
breast cancer
Novartis
ribociclib
Novartis Takes Aim at Pfizer
Motley Fool
Thu, 11/3/16 - 09:48 am
Novartis
Pfizer
breast cancer
ribociclib
Ibrance
Pfizer touts Ibrance's safety as competition intensifies
BioPharma Dive
Wed, 11/2/16 - 09:52 am
Pfizer
Ibrance
breast cancer
Pfizer Continues to Work on Ibrance Label Expansion in 2016
Market Realist
Thu, 10/27/16 - 09:14 am
Pfizer
Ibrance
breast cancer
Is This Pfizer's Next Mega-Blockbuster Cancer Drug?
Motley Fool
Tue, 09/27/16 - 10:51 am
Pfizer
Medivation
Xtandi
avelumab
Merck KGaA
Ibrance
Pfizer gets green light for Ibrance in EU
BioPharma Dive
Mon, 09/19/16 - 06:05 pm
Pfizer
Ibrance
Europe
breast cancer
How Pfizer Plans to Extend Ibrance beyond Breast Cancer Treatment
Market Realist
Fri, 09/2/16 - 11:24 am
Pfizer
Ibrance
breast cancer
head and neck cancer
lung cancer
pancreatic cancer
Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021
Market Realist
Mon, 08/29/16 - 04:16 pm
Ibrance
Xtandi
oncology
Pfizer
Medivation
breast cancer
prostate cancer
Game On for Pfizer With $14 Billion Medivation Buyout (or, Why Pfizer's Buyout of Medivation Could Be a Smart Move)
Motley Fool
Fri, 08/26/16 - 10:00 am
Pfizer
Medivation
M&A
oncology
Ibrance
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »